

Update 4/08/25

Levemir is now unavailable from most pharmacies and distributors in the United States.

Levemir will remain available in other industrialized countries for the time being.

The Alliance to Protect Insulin Choice has sent a Citizen Petition (CP) to the FDA asking for the Levemir discontinuation to be addressed.

The Alliance to Protect Insulin Choice has requested Listening Sessions with the FDA regarding Levemir. If accepted, seven individuals from the community will join a call with representatives of the FDA to discuss the difficulty many have without access to the basal insulin that allows quick changes to the amount of insulin given to match changing insulin needs. This flexibility is necessary for many of all ages, but is especially evident for many pregnant women, teens, women with a menstrual cycle, women in menopause, and athletes. We would also like to discuss the danger posed to very small children who require insulin who do not have access to the long-acting insulin that can be diluted for very small doses. Additionally, we would like to discuss possible serious complications that can occur with the few alternatives to Levemir.

Our requests:

US government leaders and the FDA to request the following of Novo Nordisk:

As Novo Nordisk is abandoning Levemir in the US, and because many patients and physicians are concerned about the likelihood of harm, we ask that Novo Nordisk sign over the FDA rights to manufacture Levemir to an organization who will ensure that a biosimilar gets made. This organization could be a non-profit, contract manufacturer or other pharmaceutical company to be determined.

We also ask that you allow Levemir to be purchased in bulk from countries where it is still available, so that it may be distributed in the U.S. until a biosimilar is available.